Asuragen said this week that it has received a notice of allowance from the US Patent and Trademark Office for claims related to the use of microRNA-205 as a diagnostic for lung cancer.
"Human miR-205 has been identified as being highly expressed in lung cancer when compared with its expression in normal lung tissue, and, as a result, is an excellent marker for use as a diagnostic for lung cancer," the company said.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
